Showing results (311-320 of 460) with videos related to
Sort By:
Pageof 46
Oncology|April 24, 2010
NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancerSoham D Puvvada, William K Funkhouser, Kevin Greene, et al.American Journal of Epidemiology|January 17, 2020
The Galaxy Plot: A New Visualization Tool for Bivariate Meta-Analysis StudiesChuan Hong, Rui Duan, Lingzhen Zeng, et al.Vaccine|March 13, 2017
Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibilityPui-Ying Iroh Tam, Beth K Thielen, Stephen K Obaro, et al.Biorxiv : the Preprint Server for Biology|August 26, 2024
Benchmarking DNA Foundation Models for Genomic Sequence ClassificationHaonan Feng, Lang Wu, Bingxin Zhao, et al.Nature Communications|November 28, 2025
Benchmarking DNA foundation models for genomic and genetic tasksHaonan Feng, Lang Wu, Bingxin Zhao, et al.International Journal of Environmental Research and Public Health|March 15, 2018
Comparative Effectiveness of Published Interventions for Elderly Fall Prevention: A Systematic Review and Network Meta-AnalysisPeixia Cheng, Liheng Tan, Peishan Ning, et al.Blood Cancer Journal|March 8, 2020
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysisShijia Zhang, Amit A Kulkarni, Beibei Xu, et al.Tobacco Regulatory Science|May 9, 2022
Analysis of Multiple Biomarkers Using Structural Equation ModelingWenhao Cao, Stephen S Hecht, Sharon E Murphy, et al.Journal of Comparative Effectiveness Research|April 7, 2025
Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparisonIsha Mol, Yannan Hu, Thomas W LeBlanc, et al.Journal of Blood Medicine|May 19, 2025
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated ResultsIsha Mol, Yannan Hu, Thomas W LeBlanc, et al.Pageof 46